Published 6 days ago • loading... • Updated 6 days ago

Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development

On Nov. 12, 2025, Ascletis Pharma Inc. announced co-formulation of ASC36 and ASC35 for clinical development, showing no aggregation or fibrillation at neutral pH and enabling once-monthly dosing.
Using its AISBDD and ULAP platforms, Ascletis Pharma Inc. discovered and developed ASC36 and ASC35 in-house, designing once-monthly subcutaneous ultra-long-acting peptides.
Head-to-Head preclinical studies found ASC35 showed 71% greater body weight reduction versus tirzepatide, ASC36 showed 32% greater reduction versus eloralintide, and their co-formulation showed 51% greater reduction versus eloralintide plus tirzepatide with comparable NHP pharmacokinetics.
Ascletis expects to submit an IND to the U.S. Food and Drug Administration in the second quarter of 2026 and will host a conference call in Mandarin at 10:00 a.m. China Standard Time on Nov. 13, 2025.
Ascletis positions ASC36 as a cornerstone once-monthly therapy, potentially paired with ASC47 in future co-formulations.

Insights by Ground AI

45 Articles

keenesentinel.com

+44 Reposted by 44 other sources

Center

Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development

Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, demonstrated a comparable pharmacokinetic (PK) profile to ASC36 and ASC35 dosed alone…

6 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year